Debra Higginbotham, MD
Family Medicine · Santa Fe, NMNPI 1861460446
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,511 and has fallen 77.3% since, to $343 in 2025. Among family medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$528
- AbbVie$462
- AstraZeneca$421
- Lilly USA, LLC$410
- Radius Health, Inc.$189
- GSK$121
- plus $559 from 15 others
What the payments were for
- Food & beverage$2,67599%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $528 |
| AbbVie(2 entities) | 25 | $462 |
| AstraZeneca | 23 | $421 |
| Lilly USA, LLC | 17 | $410 |
| Radius Health, Inc. | 5 | $189 |
| GSK | 1 | $121 |
| Amgen | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Exact Sciences | 4 | $68 |
| Novartis | 3 | $57 |
| Amarin Pharma, Inc. | 2 | $43 |
| Boehringer Ingelheim | 2 | $34 |
| Astellas Pharma US Inc | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Circassia Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Merck | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,690 in reported general payments places this provider in the 90th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 47 | $73,339 |
| MounjaroTirzepatide | 48 | $72,540 |
| FarxigaDapagliflozin Propanediol | 33 | $33,771 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,776 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $13,147 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $11,027 |
| MyrbetriqMirabegron | 11 | $9,080 |
| Rosuvastatin Calcium | 206 | $5,057 |
| Duloxetine Hcl | 84 | $4,913 |
| Estradiol | 29 | $4,667 |
| Levothyroxine Sodium | 223 | $3,417 |
| Valsartan | 42 | $1,829 |
| Famotidine | 82 | $1,745 |
| Atorvastatin Calcium | 114 | $1,732 |
| Lisinopril | 174 | $1,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $410 | $145,87895 claims |
| AstraZenecaFarxiga, Symbicort | $421 | $46,91863 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $121 | $26,80326 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $9,08011 claims |
| AbbVieSynthroid | $462 | $1,01836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Santa Fe
- Wendy JohnsonSanta Fe$37K
- Kurt KastendieckSanta Fe$7K
- Carl FriedrichsSanta Fe$7K
- Luis Rigales IiiSanta Fe$4K
- Aryan CaireSanta Fe$3K
- Karla Moya-CritesSanta Fe$3K
- Gerzain ChavezSanta Fe$3K
- Harold McFarlingFarmington$160K
- Carletta BullockAlbuquerque$60K
- Robert BairAlbuquerque$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.